The potential therapeutic efficacy of HMGB1 neutralization was investigated in a murine model of SM using an anti-HMGB1 monoclonal antibody (mAb) with previously validated therapeutic benefit in experimental sepsis models. This evidence concerns the gene HMGB1 and systemic mastocytosis.